Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations. [electronic resource]
Producer: 20200415Description: 139 p. digitalISSN:- 1476-4598
- Animals
- Antineoplastic Agents -- pharmacology
- B7-H1 Antigen -- antagonists & inhibitors
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- ErbB Receptors -- genetics
- Gene Expression Regulation, Neoplastic -- drug effects
- Humans
- Immunomodulation -- drug effects
- Lung Neoplasms -- drug therapy
- Mutation
- Neoplasm Metastasis
- Neoplasm Staging
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Protein Kinase Inhibitors -- pharmacology
- Tumor Microenvironment -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.